Yuichi Nagata1, Naoko Inoshita2, Noriaki Fukuhara3, Mitsuo Yamaguchi-Okada3, Hiroshi Nishioka3, Takeo Iwata4, Katsuhiko Yoshimoto4, Shozo Yamada3. 1. Department of Hypothalamic and Pituitary Surgery, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 105-8470, Japan. you1ngta@gmail.com. 2. Department of Pathology, Toranomon Hospital, Tokyo, Japan. 3. Department of Hypothalamic and Pituitary Surgery, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 105-8470, Japan. 4. Department of Medical Pharmacology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
Abstract
PURPOSE: Growth hormone (GH)-producing pituitary adenomas (PAs) in childhood or young adulthood are rare, and the details surrounding these tumors remain enigmatic. We present the clinical, pathological and genetic features of this disease. METHODS: We identified 25 patients aged 20 years or younger with GH-producing PAs who underwent surgery between 2003 and 2016 at Toranomon Hospital in Tokyo. We retrospectively reviewed the clinical data, treatment outcomes and pathological features of these patients to shed light on childhood acromegaly. RESULTS: The cohort comprised 14 male and 11 female patients whose average age at the time of surgery was 17.3 years. Germline AIP mutations were present in 5 of 13 patients examined, and Carney complex was identified in 2 of 25 patients. The mean maximum tumor diameter was 26.7 mm, and total resection assessed during surgery was achieved in 17 patients. Based on their respective pathological findings, patients were divided into the following 4 groups: sparsely granulated adenomas (5), densely granulated (DG) adenomas (6), plurihormonal adenomas (9), and silent subtype 3 (SS3) adenomas (5). During the mean follow-up period of 50.3 months, complete endocrinological remission was achieved in 14 of 25 patients (56%) by surgery alone and in 19 patients (76%) after postoperative adjuvant therapy. CONCLUSIONS: GH-producing PAs in young patients are intriguing and difficult to treat due to their distinct tumor characteristics, including a lower incidence of the DG subtype and a higher incidence of SS3 adenomas and genetic abnormalities. Therefore, multi-modal therapies are essential to achieve optimal clinical outcomes.
PURPOSE:Growth hormone (GH)-producing pituitary adenomas (PAs) in childhood or young adulthood are rare, and the details surrounding these tumors remain enigmatic. We present the clinical, pathological and genetic features of this disease. METHODS: We identified 25 patients aged 20 years or younger with GH-producing PAs who underwent surgery between 2003 and 2016 at Toranomon Hospital in Tokyo. We retrospectively reviewed the clinical data, treatment outcomes and pathological features of these patients to shed light on childhood acromegaly. RESULTS: The cohort comprised 14 male and 11 female patients whose average age at the time of surgery was 17.3 years. Germline AIP mutations were present in 5 of 13 patients examined, and Carney complex was identified in 2 of 25 patients. The mean maximum tumor diameter was 26.7 mm, and total resection assessed during surgery was achieved in 17 patients. Based on their respective pathological findings, patients were divided into the following 4 groups: sparsely granulated adenomas (5), densely granulated (DG) adenomas (6), plurihormonal adenomas (9), and silent subtype 3 (SS3) adenomas (5). During the mean follow-up period of 50.3 months, complete endocrinological remission was achieved in 14 of 25 patients (56%) by surgery alone and in 19 patients (76%) after postoperative adjuvant therapy. CONCLUSIONS:GH-producing PAs in young patients are intriguing and difficult to treat due to their distinct tumor characteristics, including a lower incidence of the DG subtype and a higher incidence of SS3 adenomas and genetic abnormalities. Therefore, multi-modal therapies are essential to achieve optimal clinical outcomes.
Authors: J C Watson; C A Stratakis; P K Bryant-Greenwood; C A Koch; L S Kirschner; T Nguyen; J A Carney; E H Oldfield Journal: J Neurosurg Date: 2000-03 Impact factor: 5.115
Authors: Timothy E Richardson; Derek A Mathis; Bruce E Mickey; Jack M Raisanen; Dennis K Burns; Charles L White; Kimmo J Hatanpaa Journal: J Neuropathol Exp Neurol Date: 2015-12 Impact factor: 3.685
Authors: T Cuny; T T Mac; P Romanet; H Dufour; I Morange; F Albarel; A Lagarde; F Castinetti; T Graillon; M O North; A Barlier; T Brue Journal: Pituitary Date: 2019-10 Impact factor: 4.107
Authors: M Araujo-Castro; E Pascual-Corrales; V Martínez-Vaello; G Baonza Saiz; J Quiñones de Silva; A Acitores Cancela; A M García Cano; V Rodríguez Berrocal Journal: J Endocrinol Invest Date: 2020-05-21 Impact factor: 4.256
Authors: T Feola; R Sa Pirchio; G Puliani; R Pofi; M Crocco; V Sada; F Sesti; F Verdecchia; D Gianfrilli; M Appetecchia; N Di Iorgi; M L Jaffrain-Rea; R Pivonello; A M Isidori; A B Grossman; E Sbardella Journal: J Endocrinol Invest Date: 2022-08-24 Impact factor: 5.467
Authors: John P Andrews; Rushikesh S Joshi; Matheus P Pereira; Taemin Oh; Alexander F Haddad; Kaitlyn M Pereira; Robert C Osorio; Kevin C Donohue; Zain Peeran; Sweta Sudhir; Saket Jain; Angad Beniwal; Ashley S Chopra; Narpal S Sandhu; Tarik Tihan; Lewis Blevins; Manish K Aghi Journal: World Neurosurg Date: 2021-04-20 Impact factor: 2.210
Authors: Medard F M van den Broek; Bernadette P M van Nesselrooij; Annemarie A Verrijn Stuart; Rachel S van Leeuwaarde; Gerlof D Valk Journal: Front Endocrinol (Lausanne) Date: 2019-12-10 Impact factor: 5.555